Illumina, Inc. (ILMN)

117.43 +0.74 (+0.63%) 收市：04:00PM EDT

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500
https://www.illumina.com

版塊: Healthcare
行業: Diagnostics & Research
全職員工: 10,590

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Jacob Thaysen Ph.D.	CEO & Director	796.63k	無	1975
Ms. Carissa L. Rollins	Chief Information Officer	693.52k	無	1970
Mr. Charles E. Dadswell Esq.	Senior VP & General Counsel	1.03M	無	1959
Stephanie Campos	President	無	無	無
Mr. Ankur Dhingra	Chief Financial Officer	無	無	1976
Mr. Kevin Carl Pegels	Chief of Global Operations	無	無	1968
Mr. Scott Ericksen	VP & Chief Accounting Officer	無	無	1973
Dr. Steven Barnard Ph.D.	Chief Technology Officer	無	無	無
Ms. Sallilyn Schwartz	Vice President of Investor Relations	無	無	無
Mr. Jakob Wedel	Chief Strategy & Corporate Development Officer and CEO Chief of Staff	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

公司管治

截至 2024年4月1日 止，Illumina, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：9；董事會：8；股東權利：7；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。